Concepedia

Allan Wu

AW

Statistics

Publications

11

Citations

635

H-Index

11

Active since

2012

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (United Kingdom)

AstraZeneca (Sweden)

Allan Wu is an author at AstraZeneca (United States) specializing in drug discovery, pharmacology, and medicinal chemistry.

Publications per year

2012–2023

11

Publications

11

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia

Erika Krasnickas Keeton, Kristen McEachern, Keith Dillman et al. · Blood · 2013 · 247 citations

, , +11

Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases

Les A. Dakin, Huawei Chen, Erin Code et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 101 citations · Full text

, , +14

Discovery of (2<i>R</i>)-<i>N</i>-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1<i>H</i>-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor

Qibin Su, Erica Banks, Geraldine Bebernitz et al. · Journal of Medicinal Chemistry · 2020 · 60 citations · Full text

, , +15

Structure‐Based Design of Selective Noncovalent CDK12 Inhibitors

Jeffrey W. Johannes, Christopher R. Denz, Nancy Su et al. · ChemMedChem · 2017 · 52 citations

, , +13

Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization

James J. Dowling, Claudio Chuaqui, Timothy Pontz et al. · ACS Medicinal Chemistry Letters · 2012 · 47 citations · Full text

, , +17

1–5 of 11